Overview

Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy and safety of low-dose IL-2 in the treatment of immunorelated ALS syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University Third Hospital